Following on from Module 1, The Use of Immunotherapy in HCC: Efficacy and Safety, you can now go deeper with your learning in Module 2, The Use of Immunotherapy in HCC: In-depth Subgroup Analyses and Challenges, brought to you by HCC experts Prof. Peter R. Galle and Dr Aiwu Ruth He.

 

In this module, you'll learn about current data and the efficacy and challenges of immunotherapy (IO) for different subgroups of patients with hepatocellular carcinoma (HCC), including how to:

  • Assess liver function using the Albumin-Bilirubin (ALBI) scoring system to evaluate a patient's eligibility for IO treatment
  • Understand the efficacy and safety data in the different subgroups eligible for IO treatment

 

Watch the 4-minute video and download the accompanying slides and flashcard for your reference.

When you're ready to test your knowledge, take the assessment using the blue button beneath the video.

 

Clinical Takeaways

  • The Child-Pugh and ALBI scoring systems are methods to assess liver function

  • There is a need to understand whether specific groups of patients with HCC benefit more from one systemic treatment than another

  • Subgroup analyses in patients with HCC receiving IO and IO combinations show variable hazard ratios across etiologies and liver function. These data are not mature enough to guide treatment decisions

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

 

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

 

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

 

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Prof. Aiwu Ruth He has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Boston Scientific, Eisai, Genentech and Merck.

Programme summary
Take the micro learning now
Other episodes of this series
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 1: Efficacy and Safety

The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 2: In-depth Subgroup Analyses and Challenges

Current Module
The expanding role of immunotherapy in HCC

The expanding role of immunotherapy in HCC

Module 3: Combining locoregional and systemic treatments in intermediate HCC

Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Accreditation and Endorsement
EACCME
This course has been accredited by EACCME® for ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

publication Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
video Video
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
interactive-patient-case Interactive patient case
Oncology 
NTRK fusion testing and treatment in pediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
interactive-patient-case Interactive patient case
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
DiCE ICAN international cancer advocacy network
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025

Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Prof. Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED